Abstract
Bullous pemphigoid is a common subepidermal autoimmune bullous disease that affects the skin and mucous membranes. It is more prevalent in the elderly, often resulting in significant morbidity and mortality. Bullous pemphigoid is rare in solid organ transplant recipients but presents unique challenges due to their underlying immunosuppression, which increases the risks of infection and adverse drug reactions. Herein, we present the first reported case of dupilumab successfully treating bullous pemphigoid in a liver transplant recipient.